Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

A. Diab; C. Haymaker; C. Bernatchez; R. H.I. Andtbacka; M. Shaheen; D. Johnson; J. Markowitz; I. Puzanov; R. Murthy; D. H. Johnson; M. James; S. Chunduru; J. Geib; S. Swann; S. Rahimian; P. Hwu

doi:10.1093/annonc/mdy289.001

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

A. Diab, C. Haymaker, C. Bernatchez, R. H.I. Andtbacka, M. Shaheen, D. Johnson, J. Markowitz, I. Puzanov, R. Murthy, D. H. Johnson, M. James, S. Chunduru, J. Geib, S. Swann, S. Rahimian, P. Hwu

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	viii442
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy289.001
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy289.001

Cite this

Diab, A., Haymaker, C., Bernatchez, C., Andtbacka, R. H. I., Shaheen, M., Johnson, D., Markowitz, J., Puzanov, I., Murthy, R., Johnson, D. H., James, M., Chunduru, S., Geib, J., Swann, S., Rahimian, S., & Hwu, P. (2018). Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii442. https://doi.org/10.1093/annonc/mdy289.001

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. / Diab, A.; Haymaker, C.; Bernatchez, C. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii442.

Research output: Contribution to journal › Article › peer-review

Diab, A , Haymaker, C, Bernatchez, C, Andtbacka, RHI, Shaheen, M, Johnson, D, Markowitz, J, Puzanov, I, Murthy, R, Johnson, DH, James, M, Chunduru, S, Geib, J, Swann, S, Rahimian, S & Hwu, P 2018, 'Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii442. https://doi.org/10.1093/annonc/mdy289.001

Diab A , Haymaker C, Bernatchez C, Andtbacka RHI, Shaheen M, Johnson D et al. Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii442. doi: 10.1093/annonc/mdy289.001

Diab, A. ; Haymaker, C. ; Bernatchez, C. et al. / Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM) : Results from a multicenter, phase I/II study. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2018 ; Vol. 29. pp. viii442.

@article{f014bd54cb7d44d0bc98fe4822cd74c2,

title = "Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study",

author = "A. Diab and C. Haymaker and C. Bernatchez and Andtbacka, {R. H.I.} and M. Shaheen and D. Johnson and J. Markowitz and I. Puzanov and R. Murthy and Johnson, {D. H.} and M. James and S. Chunduru and J. Geib and S. Swann and S. Rahimian and P. Hwu",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy289.001",

language = "English (US)",

volume = "29",

pages = "viii442",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM)

T2 - Results from a multicenter, phase I/II study

AU - Diab, A.

AU - Haymaker, C.

AU - Bernatchez, C.

AU - Andtbacka, R. H.I.

AU - Shaheen, M.

AU - Johnson, D.

AU - Markowitz, J.

AU - Puzanov, I.

AU - Murthy, R.

AU - Johnson, D. H.

AU - James, M.

AU - Chunduru, S.

AU - Geib, J.

AU - Swann, S.

AU - Rahimian, S.

AU - Hwu, P.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85077660766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077660766&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy289.001

DO - 10.1093/annonc/mdy289.001

M3 - Article

C2 - 32137127

SN - 0923-7534

VL - 29

SP - viii442

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this